A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 in Healthy Subjects and in Subjects With Rheumatoid Arthritis (RA) Also Treated With Methotrexate

Trial Profile

A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 in Healthy Subjects and in Subjects With Rheumatoid Arthritis (RA) Also Treated With Methotrexate

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs MBS 2320 (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Modern Biosciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2017 Status changed from recruiting to completed.
    • 10 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top